GSK3B polymorphisms alter transcription and splicing in Parkinson's disease
about
Regulation of mitochondrial functions by protein phosphorylation and dephosphorylationNeuroimaging in psychiatric pharmacogenetics research: the promise and pitfallsUncovering novel actors in astrocyte-neuron crosstalk in Parkinson's disease: the Wnt/β-catenin signaling cascade as the common final pathway for neuroprotection and self-repairThe regulation and deregulation of Wnt signaling by PARK genes in health and diseaseGSK-3β dysregulation contributes to parkinson's-like pathophysiology with associated region-specific phosphorylation and accumulation of tau and α-synucleinThe importance of Wnt signalling for neurodegeneration in Parkinson's diseaseThe protease Omi regulates mitochondrial biogenesis through the GSK3β/PGC-1α pathwayAlpha-synuclein and tau: teammates in neurodegeneration?Molecular actions and clinical pharmacogenetics of lithium therapyGSK3B and MAPT polymorphisms are associated with grey matter and intracranial volume in healthy individualsA Wnt1 regulated Frizzled-1/β-Catenin signaling pathway as a candidate regulatory circuit controlling mesencephalic dopaminergic neuron-astrocyte crosstalk: Therapeutical relevance for neuron survival and neuroprotectionCanonical correlation analysis for RNA-seq co-expression networksThe Ddx5 and Ddx17 RNA helicases are cornerstones in the complex regulatory array of steroid hormone-signaling pathwaysGSK-3: Functional Insights from Cell Biology and Animal Models.Alpha-Synuclein contributes to GSK-3beta-catalyzed Tau phosphorylation in Parkinson's disease models.MAPT rs242562 and GSK3B rs334558 are associated with Parkinson's Disease in central China.Targeting Wnt signaling at the neuroimmune interface for dopaminergic neuroprotection/repair in Parkinson's disease.GSK3beta: role in therapeutic landscape and development of modulators.DNA methylation of the MAPT gene in Parkinson's disease cohorts and modulation by vitamin E in vitroElevated tauopathy and alpha-synuclein pathology in postmortem Parkinson's disease brains with and without dementiaHaplotype analysis of GSK-3β gene polymorphisms in bipolar disorder lithium responders and nonresponders.The association of glycogen synthase kinase-3beta (GSK-3β) gene polymorphism with kidney function in long-term lithium-treated bipolar patients.Tauopathic changes in the striatum of A53T α-synuclein mutant mouse model of Parkinson's disease.GSK-3 in Neurodegenerative Diseases.Truncation and activation of GSK-3β by calpain I: a molecular mechanism links to tau hyperphosphorylation in Alzheimer's disease.Paclitaxel-induced neuropathy: potential association of MAPT and GSK3B genotypesPINK1 enhances insulin-like growth factor-1-dependent Akt signaling and protection against apoptosis.Lovastatin protects neurite degeneration in LRRK2-G2019S parkinsonism through activating the Akt/Nrf pathway and inhibiting GSK3β activity.Role of the Long Non-Coding RNA MAPT-AS1 in Regulation of Microtubule Associated Protein Tau (MAPT) Expression in Parkinson's Disease.Site-specific phosphorylation protects glycogen synthase kinase-3β from calpain-mediated truncation of its N and C termini.Possible association of the GSK3β gene with the anxiety symptoms of major depressive disorder and P300 waveform.Lithium and GSK3-β promoter gene variants influence white matter microstructure in bipolar disorderTargeting glycogen synthase kinase-3 as an approach to develop novel mood-stabilising medications.From DNA to RNA to disease and back: the 'central dogma' of regulatory disease variation.Single-nucleotide polymorphisms of GSK3B, GAB2 and SORL1 in late-onset Alzheimer's disease: interactions with the APOE genotypeFluticasone propionate pharmacogenetics: CYP3A4*22 polymorphism and pediatric asthma control.An evaluation of the impact of MAPT, SNCA and APOE on the burden of Alzheimer's and Lewy body pathology.Variation in tau isoform expression in different brain regions and disease statesLRRK2: an éminence grise of Wnt-mediated neurogenesis?Glycogen synthase kinase 3beta missplicing contributes to leukemia stem cell generation.
P2860
Q26752880-A59AFE8D-D2E6-44B7-8BA9-4868821C8964Q26853551-2D7C525C-106F-451B-ADA2-E4D4662BA8D7Q26865502-EFC75502-A444-42ED-BA5D-12E5B492173EQ26991986-67ED0177-FBCC-4B06-B94A-FAD76C5FB584Q27331743-2AA78598-3F2B-444F-AB7D-7B3F8803D3E1Q28115237-A069B39A-F4CE-4A3B-A81D-97AD97DE6D02Q28117215-110DB686-C4DF-4C5D-97BB-359DD1BE2EC5Q28250508-7B34D03C-F759-4FE2-9E77-84757764C245Q28307770-B5561D72-8E51-4419-BF3E-35146796A7F1Q28535250-FA45CEB9-886B-4246-B2CC-5C79CE2F64A4Q28589470-E7D99D54-7ED9-42A6-823D-C0B38326A921Q28708868-3AF93726-2F25-40A6-BD2C-BC592BC02BB9Q28854594-2B617B59-79F3-467F-83F4-7BAD32D8BE39Q30472813-3EF233F2-B216-457E-ACD3-071CCAAF5BA5Q33552220-1372A524-1D12-49DA-BFF5-73380A34C1DEQ33611508-52BFCF3B-881F-4249-8D16-E7F96F7A4381Q33771694-F06B79D2-7ADB-47D2-8911-8E650B81BE1FQ33812730-7C589E21-98E4-4651-BE42-57F0D93055FBQ33818001-3CA2EB4D-04C3-445D-8032-36F98B87F5D0Q34069284-97D65E89-4698-4176-A139-3DF05D8F54C1Q34387978-5A3D588F-301B-43D7-A754-A23B48810A00Q34502691-3ECC25A6-2CB7-4B2E-A491-4A6F6282BE42Q34704153-C424088E-5857-41A6-8234-8D7AEF950456Q35001040-224C819E-BE49-414B-B8CC-DB2763F165F6Q35035648-2EC71FAF-3EB5-4BE4-9FCB-AE049DA098AAQ35191233-2410C9B6-1DC8-4F54-BD30-BD1F01900FF6Q35577571-C1D7BE81-CA42-4A30-856B-E2C1C6433324Q35941717-9EB40A97-D617-41DB-BD4F-9C357ACEEE6EQ36060128-27CB5A2A-ADA0-43C2-8672-BFF3EAAFAFA2Q36080538-B4E48CED-2154-4709-BB4A-C69381323726Q36408114-097CB064-D9C4-4CEF-A463-CBDD2F37EEF5Q36480123-247E6B7E-4A50-4A38-A533-4788B0B33AB7Q36481051-D94ECE2E-8D7A-46B9-A030-A83FC43A96C5Q36539664-4DF05453-85E9-4F45-9B41-B73F88A447F0Q36644694-9036E1D1-ADAD-4A23-814C-B59EC8777F48Q36750899-1AAF5DDE-4606-4831-B47B-80E1CE069790Q36758618-84801043-580C-4F40-A57C-05B4981E9DF0Q36812266-9FA2A693-B544-4FF4-B87F-923E29C120D0Q36888947-796CF46B-B1F7-4CFC-B349-6739B84B640BQ37106907-EB129189-EA04-43BF-BF61-B79B8BC9CB62
P2860
GSK3B polymorphisms alter transcription and splicing in Parkinson's disease
description
2005 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
artículu científicu espublizáu en 2005
@ast
im Dezember 2005 veröffentlichter wissenschaftlicher Artikel
@de
scientific journal article
@en
vedecký článok (publikovaný 2005/12/01)
@sk
vědecký článek publikovaný v roce 2005
@cs
wetenschappelijk artikel (gepubliceerd op 2005/12/01)
@nl
наукова стаття, опублікована в грудні 2005
@uk
مقالة علمية (نشرت في ديسمبر 2005)
@ar
name
GSK3B polymorphisms alter transcription and splicing in Parkinson's disease
@ast
GSK3B polymorphisms alter transcription and splicing in Parkinson's disease
@en
GSK3B polymorphisms alter transcription and splicing in Parkinson's disease
@nl
type
label
GSK3B polymorphisms alter transcription and splicing in Parkinson's disease
@ast
GSK3B polymorphisms alter transcription and splicing in Parkinson's disease
@en
GSK3B polymorphisms alter transcription and splicing in Parkinson's disease
@nl
prefLabel
GSK3B polymorphisms alter transcription and splicing in Parkinson's disease
@ast
GSK3B polymorphisms alter transcription and splicing in Parkinson's disease
@en
GSK3B polymorphisms alter transcription and splicing in Parkinson's disease
@nl
P2093
P50
P921
P3181
P356
P1433
P1476
GSK3B polymorphisms alter transcription and splicing in Parkinson's disease
@en
P2093
Clement T Loy
Daniel K Y Chan
Marianne Hallupp
Peter A Silburn
P304
P3181
P356
10.1002/ANA.20691
P577
2005-12-01T00:00:00Z